Japan Chemical Research And Asuka Pharma To Develop New Biotech Drug To Treat MPS
This article was originally published in PharmAsia News
Japan Chemical Research and Tokyo-based Asuka Pharmaceuticals will jointly develop and market a drug to treat mucopolysaccharidosis (MPS), a type of genetic liposomal storage disorder. The biotech drug uses genetic modification technology, and it was cultured under serum-free conditions. By not using cow blood serum, the companies say it is more cost efficient and eliminates the risk of BSE infections. Asuka and Japan Chemical hope to enter the drug into clinic trials soon. (Click here for more - may require subscription
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.